BioVaxys Technology (BioVaxys Technology) Cash And Cash Equivalents : $0.00 Mil (As of Jul. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Cash And Cash Equivalents?

BioVaxys Technology's quarterly cash and cash equivalents declined from Jan. 2023 ($0.05 Mil) to Apr. 2023 ($0.02 Mil) but then stayed the same from Apr. 2023 ($0.02 Mil) to Jul. 2023 ($0.00 Mil).

BioVaxys Technology's annual cash and cash equivalents declined from Oct. 2020 ($1.83 Mil) to Oct. 2021 ($0.48 Mil) and declined from Oct. 2021 ($0.48 Mil) to Oct. 2022 ($0.10 Mil).

BioVaxys Technology Cash And Cash Equivalents Historical Data

The historical data trend for BioVaxys Technology's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology Cash And Cash Equivalents Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Cash And Cash Equivalents

0.01

0.17

1.83

0.48

0.10

BioVaxys Technology Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.03	0.10	0.05	0.02	-

BioVaxys Technology Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

BioVaxys Technology (OTCPK:BVAXF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

BioVaxys Technology Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology (BioVaxys Technology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumor types.